Literature DB >> 12393477

High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease.

Richard K Burt1, Ann Traynor, Yu Oyama, Robert Craig.   

Abstract

Two patients with severe Crohn disease, defined by a Crohn Disease Activity Index (CDAI) higher than 250 despite anti-tumor necrosis factor alpha (TNF-alpha), were treated by intense immune suppression and autologous hematopoietic stem cell transplantation (HSCT). Stem cells were mobilized from the peripheral blood using cyclophosphamide (2.0 g/m2) and granulocyte colony-stimulating factor (G-CSF; 5 micro g/kg/d), enriched ex vivo by CD34+ selection, and reinfused after immune conditioning with cyclophosphamide (200 mg/kg) and equine anti-thymocyte globulin (ATG; 90 mg/kg). Patients have remained in remission (CDAI < 100) for 1 year since HSCT. We conclude that further HSCT studies for severe Crohn disease appear warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393477     DOI: 10.1182/blood-2002-07-2122

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  Cellular and molecular mechanisms of the epithelial repair in IBD.

Authors:  Ryuichi Okamoto; Mamoru Watanabe
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 2.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 3.  Inflammatory bowel disease: Moving toward a stem cell-based therapy.

Authors:  Giacomo Lanzoni; Giulia Roda; Andrea Belluzzi; Enrico Roda; Gian Paolo Bagnara
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

Review 4.  Regeneration of the intestinal epithelia: regulation of bone marrow-derived epithelial cell differentiation towards secretory lineage cells.

Authors:  Ryuichi Okamoto; Tomoko Matsumoto; Mamoru Watanabe
Journal:  Hum Cell       Date:  2006-05       Impact factor: 4.174

5.  Complete resolution of severe ulcerative colitis after haploidentical hematopoietic stem cell transplantation followed by post-transplant high-dose cyclophosphamide.

Authors:  A Unnikrishnan; S C Glover; O Norkina; J R Wingard; M Norkin
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

6.  Advancements in gene transfer-based therapy for hemophilia A.

Authors:  Christopher B Doering; H Trent Spencer
Journal:  Expert Rev Hematol       Date:  2009-12       Impact factor: 2.929

7.  Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research.

Authors:  Marcelo C Pasquini; Julio Voltarelli; Harold L Atkins; Nelson Hamerschlak; Xiaobo Zhong; Kwang Woo Ahn; Keith M Sullivan; George Carrum; Jeffrey Andrey; Christopher N Bredeson; Mitchell Cairo; Robert Peter Gale; Theresa Hahn; Jan Storek; Mary M Horowitz; Peter A McSweeney; Linda M Griffith; Paolo A Muraro; Steven Z Pavletic; Richard A Nash
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-13       Impact factor: 5.742

8.  Leukocytapheresis: An "Out-of-Body" Experience in Inflammatory Bowel Disease.

Authors:  Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-12

Review 9.  Management of inflammatory bowel disease.

Authors:  M Nayar; J M Rhodes
Journal:  Postgrad Med J       Date:  2004-04       Impact factor: 2.401

10.  Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis.

Authors:  Eric Hyun; Patricia Andrade-Gordon; Martin Steinhoff; Paul L Beck; Nathalie Vergnolle
Journal:  Inflamm Res       Date:  2010-03-26       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.